Volume 91, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Elevation of serum B-cell activating factor (BAFF) is one of the characteristics of immunological disorders, including autoimmunity, but the levels of BAFF in infectious diseases have not been studied well. Here, we showed the elevation of serum BAFF in patients with visceral leishmaniasis (VL). The mean serum BAFF value in VL patients (4.65 ng/mL) was 4.3 times higher than that of healthy controls (1.08 ng/mL), and 90% of VL patients showed serum BAFF above the cutoff that was calculated as the mean + 3 SDs of the controls. This report is the first on elevation of serum BAFF during VL.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Haldar JP, Ghose S, Saha KC, Ghose AC, , 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702707. [Google Scholar]
  2. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD, Jr, 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 20662069.[Crossref] [Google Scholar]
  3. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG, , 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324329.[Crossref] [Google Scholar]
  4. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM, , 2005. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania . J Exp Med 201: 747754.[Crossref] [Google Scholar]
  5. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK, , 1980. Serological investigations on Indian kala-azar. Clin Exp Immunol 40: 318326. [Google Scholar]
  6. Tangye SG, Bryant VL, Cuss AK, Good KL, , 2006. BAFF, APRIL and human B cell disorders. Semin Immunol 18: 305317.[Crossref] [Google Scholar]
  7. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T, , 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166: 610.[Crossref] [Google Scholar]
  8. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F, , 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109: 5968.[Crossref] [Google Scholar]
  9. Briones J, Timmerman JM, Hilbert DM, Levy R, , 2002. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 30: 135141.[Crossref] [Google Scholar]
  10. Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, Dillon SR, Harder B, Gross JA, Ansell SM, , 2006. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107: 28822888.[Crossref] [Google Scholar]
  11. Nduati E, Gwela A, Karanja H, Mugyenyi C, Langhorne J, Marsh K, Urban BC, , 2011. The plasma concentration of the B cell activating factor is increased in children with acute malaria. J Infect Dis 204: 962970.[Crossref] [Google Scholar]
  12. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S, , 2006. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54: 192201.[Crossref] [Google Scholar]
  13. Bermejo DA, Amezcua-Vesely MC, Montes CL, Merino MC, Gehrau RC, Cejas H, Acosta-Rodriguez EV, Gruppi A, , 2010. BAFF mediates splenic B cell response and antibody production in experimental Chagas disease. PLoS Negl Trop Dis 4: e679.[Crossref] [Google Scholar]
  14. Goto Y, Carter D, Reed SG, , 2008. Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun 76: 39673974.[Crossref] [Google Scholar]
  15. Goto Y, Coler RN, Guderian J, Mohamath R, Reed SG, , 2006. Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun 74: 39393945.[Crossref] [Google Scholar]
  16. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL, , 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 16971710.[Crossref] [Google Scholar]
  17. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N, , 2009. Interleukin 17 acts in synergy with B-cell activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10: 778785.[Crossref] [Google Scholar]
  18. Scholzen A, Teirlinck AC, Bijker EM, Roestenberg M, Hermsen CC, Hoffman SL, Sauerwein RW, , 2014. BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in controlled human malaria infection. J Immunol 192: 37193729.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 27 Apr 2014
  • Accepted : 20 Jul 2014
  • Published online : 05 Nov 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error